It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The details of the pediatric immune system that supports induction of antibodies capable of neutralizing geographically-diverse or heterologous HIV-1 is currently unclear. Here we explore the pediatric immune environment in neonatal macaque undergoing Simian-HIV infection. Simian-HIV infection of 11 pairs of therapy-naive dams and infant rhesus macaques for 24 months results in heterologous HIV-1 neutralizing antibodies in 64% of young macaques compared to 18% of adult macaques. Heterologous HIV-1 neutralizing antibodies emerge by 12 months post-infection in young macaques, in association with lower expression of immunosuppressive genes, fewer germinal center CD4 + T regulatory cells, and a lower ratio of CD4 + T follicular regulatory to helper cells. Antibodies from peripheral blood B cells in two young macaques following SHIV infection neutralize 13% of 119 heterologous HIV-1 strains and map to regions of canonical broadly neutralizing antibody epitopes on the envelope surface protein. Here we show that pediatric immunity to SHIV infection in a macaque model may inform vaccine strategies to induce effective HIV-1 neutralizing antibodies in infants and children prior to viral exposure.
The specifics of the pediatric immune response that gives rise to antibodies capable of neutralising diverse HIV-1 strains is not fully understood. Here the authors characterise the immune environment of Simian-HIV infected paediatric macaques and link to antibody neutralisation induction.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Duke University School of Medicine, Duke Human Vaccine Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)
2 University of Pennsylvania, Departments of Medicine and Microbiology, Perelman School of Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
3 Duke University School of Medicine, Department of Surgery, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)
4 Fred Hutchinson Cancer Center, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622)
5 Duke University School of Medicine, Duke Human Vaccine Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Integrative Immunobiology, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Pediatrics, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)
6 Duke University School of Medicine, Duke Human Vaccine Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Medicine, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)
7 Los Alamos National Laboratory, Los Alamos, USA (GRID:grid.148313.c) (ISNI:0000 0004 0428 3079)
8 Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
9 Duke University School of Medicine, Duke Human Vaccine Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Surgery, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Integrative Immunobiology, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Molecular Genetics and Microbiology, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)
10 BIOQUAL Inc., Rockville, USA (GRID:grid.282501.c) (ISNI:0000 0000 8739 6829)
11 Duke University School of Medicine, Duke Human Vaccine Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Surgery, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)
12 Duke University School of Medicine, Duke Human Vaccine Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Surgery, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University School of Medicine, Department of Integrative Immunobiology, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)